Cargando…

Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells

The Src family of non-receptor tyrosine kinases are frequently activated in pancreatic ductal adenocarcinoma (PDAC), contributing to disease progression through downregulation of E-cadherin and induction of epithelial-to-mesenchymal transition (EMT). The purpose of this study was to examine the effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dosch, Austin R., Dai, Xizi, Gaidarski III, Alexander A., Shi, Chanjuan, Castellanos, Jason A., VanSaun, Michael N., Merchant, Nipun B., Nagathihalli, Nagaraj S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383685/ https://www.ncbi.nlm.nih.gov/pubmed/30800218 http://dx.doi.org/10.18632/oncotarget.26621

Ejemplares similares

Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells
por: Nagathihalli, Nagaraj S., et al.
Publicado: (2016)

Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth
por: Messaggio, Fanuel, et al.
Publicado: (2017)

Emerging targets in pancreatic cancer: epithelial–mesenchymal transition and cancer stem cells
por: Castellanos, Jason A, et al.
Publicado: (2013)

New mechanistic insights into modifiable risk factors that promote pancreatic cancer
por: Srinivasan, Supriya, et al.
Publicado: (2019)

Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response
por: Walsh, Alex J., et al.
Publicado: (2016)

Stroma secreted IL6 selects for “stem-like” population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways
por: Kesh, Kousik, et al.
Publicado: (2020)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
por: Mehra, Siddharth, et al.
Publicado: (2023)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Modulation of the Leptin Receptor Mediates Tumor Growth and Migration of Pancreatic Cancer Cells
por: Mendonsa, Alisha M., et al.
Publicado: (2015)

Deciphering high risk molecular alterations in gastrointestinal malignancy utilizing an extreme outlier strategy
por: Dosch, Austin R., et al.
Publicado: (2020)

Emerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer
por: Mehra, Siddharth, et al.
Publicado: (2022)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2022)

HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib
por: deBlacam, C, et al.
Publicado: (2011)

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
por: Lee, Dajeong, et al.
Publicado: (2020)

Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress
por: Mehra, Siddharth, et al.
Publicado: (2021)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
por: XIAO, JUAN, et al.
Publicado: (2015)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Hepatocellular Proliferation Correlates with Inflammatory Cell and Cytokine Changes in a Murine Model of Nonalchoholic Fatty Liver Disease
por: VanSaun, Michael N., et al.
Publicado: (2013)

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1
por: Olou, Appolinaire A., et al.
Publicado: (2022)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
por: Fazakas, Csilla, et al.
Publicado: (2018)

Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury
por: Macfarlane, James G., et al.
Publicado: (2020)

The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
por: Appel, Camilla Kristine, et al.
Publicado: (2017)

Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells
por: Alcalá, Sonia, et al.
Publicado: (2020)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
por: Id Boufker, Hichame, et al.
Publicado: (2010)

Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling
por: WU, JIANGHONG, et al.
Publicado: (2013)

Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
por: Takiguchi, Eri, et al.
Publicado: (2017)

Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells
por: Manley, Sharon J., et al.
Publicado: (2022)

Correction: Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells
por: Manley, Sharon J., et al.
Publicado: (2022)

Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin
por: Kong, De-Bo, et al.
Publicado: (2017)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Author Correction: The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
por: Appel, Camilla Kristine, et al.
Publicado: (2019)

Desmoglein 3, via an Interaction with E-cadherin, Is Associated with Activation of Src
por: Tsang, Siu Man, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ajrff3giv06p3rftco8rcjhdlu